Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?
Posted on June 14th, 2017 by Betsy Davis in Pharmacovigilance
The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice as the amount of literature and data continues to increase. While scientific literature remains a reliable and crucial source for adverse events, successfully monitoring is becoming a greater challenge.
So what are today’s top companies doing differently to find ADRs quickly and comprehensively? What practices have they discovered to help them screen the growing deluge of literature? Are they facing common challenges and obstacles?
We at Elsevier are looking for the answers to questions such as these so that we can put together a report that examines the role of literature monitoring in the practices of the industry’s leading pharmacovigilance groups. That’s why we need you. By participating in our anonymous, 15-minute survey, you can help us create this report – and we will send participants a free copy of our key findings this summer.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Senior Strategic Marketing Manager
- Webinar: Using machine learning to identify adverse events from scientific literature
- Why literature is a valuable source for signal detection: From the EU point of view
- Elsevier uses machine learning to benefit pharmacovigilance
- How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance
- Are Drug-Drug Interactions Today’s Biggest Health Threat?